PDCD1 and cancer: In addition, SHP099 boosts T-cell activity in the mouse model, and the combination of SHP099 and anti-PD-1 could kill tumor cells more efficiently, demonstrating that SHP2 is a potentially viable therapeutic method for cancer therapy [24].